These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 11140333)

  • 1. Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility.
    Segman RH; Heresco-Levy U; Finkel B; Inbar R; Neeman T; Schlafman M; Dorevitch A; Yakir A; Lerner A; Goltser T; Shelevoy A; Lerer B
    Psychopharmacology (Berl); 2000 Nov; 152(4):408-13. PubMed ID: 11140333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacogenetic assessment of antipsychotic-induced tardive dyskinesia: contribution of 5-hydroxytryptamine 2C receptor gene and of a combination of dopamine D3 variant allele (Gly) and MnSOD wild allele (Val)].
    Zhang Z; Hou G; Zhang X; Yao H; Sha W; Zhang X
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2003 Apr; 20(2):98-102. PubMed ID: 12673575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia.
    Segman R; Neeman T; Heresco-Levy U; Finkel B; Karagichev L; Schlafman M; Dorevitch A; Yakir A; Lerner A; Shelevoy A; Lerer B
    Mol Psychiatry; 1999 May; 4(3):247-53. PubMed ID: 10395214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism.
    Lerer B; Segman RH; Fangerau H; Daly AK; Basile VS; Cavallaro R; Aschauer HN; McCreadie RG; Ohlraun S; Ferrier N; Masellis M; Verga M; Scharfetter J; Rietschel M; Lovlie R; Levy UH; Meltzer HY; Kennedy JL; Steen VM; Macciardi F
    Neuropsychopharmacology; 2002 Jul; 27(1):105-19. PubMed ID: 12062911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia.
    Segman RH; Heresco-Levy U; Finkel B; Goltser T; Shalem R; Schlafman M; Dorevitch A; Yakir A; Greenberg D; Lerner A; Lerer B
    Mol Psychiatry; 2001 Mar; 6(2):225-9. PubMed ID: 11317227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association analysis of the dopamine D3 receptor gene ser9gly and brain-derived neurotrophic factor gene val66met polymorphisms with antipsychotic-induced persistent tardive dyskinesia and clinical expression in Chinese schizophrenic patients.
    Liou YJ; Liao DL; Chen JY; Wang YC; Lin CC; Bai YM; Yu SC; Lin MW; Lai IC
    Neuromolecular Med; 2004; 5(3):243-51. PubMed ID: 15626824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients.
    Steen VM; Løvlie R; MacEwan T; McCreadie RG
    Mol Psychiatry; 1997 Mar; 2(2):139-45. PubMed ID: 9106238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between the Ser9Gly polymorphism of the dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients.
    Liao DL; Yeh YC; Chen HM; Chen H; Hong CJ; Tsai SJ
    Neuropsychobiology; 2001; 44(2):95-8. PubMed ID: 11490179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic study of BDNF, DRD3, and their interaction in tardive dyskinesia.
    Zai CC; Tiwari AK; De Luca V; Müller DJ; Bulgin N; Hwang R; Zai GC; King N; Voineskos AN; Meltzer HY; Lieberman JA; Potkin SG; Remington G; Kennedy JL
    Eur Neuropsychopharmacol; 2009 May; 19(5):317-28. PubMed ID: 19217756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazine-treated schizophrenic patients.
    Gunes A; Scordo MG; Jaanson P; Dahl ML
    Psychopharmacology (Berl); 2007 Mar; 190(4):479-84. PubMed ID: 17102980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tardive dyskinesia and DRD3, HTR2A and HTR2C gene polymorphisms in Russian psychiatric inpatients from Siberia.
    Al Hadithy AF; Ivanova SA; Pechlivanoglou P; Semke A; Fedorenko O; Kornetova E; Ryadovaya L; Brouwers JR; Wilffert B; Bruggeman R; Loonen AJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Apr; 33(3):475-81. PubMed ID: 19439249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of the Ser9Gly polymorphism in the dopamine D3 receptor gene with tardive dyskinesia in Korean schizophrenics.
    Woo SI; Kim JW; Rha E; Han SH; Hahn KH; Park CS; Sohn JW
    Psychiatry Clin Neurosci; 2002 Aug; 56(4):469-74. PubMed ID: 12109967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of dopamine D3-receptor gene variants with neuroleptic induced akathisia in schizophrenic patients: a generalization of Steen's study on DRD3 and tardive dyskinesia.
    Eichhammer P; Albus M; Borrmann-Hassenbach M; Schoeler A; Putzhammer A; Frick U; Klein HE; Rohrmeier T
    Am J Med Genet; 2000 Apr; 96(2):187-91. PubMed ID: 10893495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction between polymorphisms of the dopamine D3 receptor and manganese superoxide dismutase genes in susceptibility to tardive dyskinesia.
    Zhang ZJ; Zhang XB; Hou G; Yao H; Reynolds GP
    Psychiatr Genet; 2003 Sep; 13(3):187-92. PubMed ID: 12960753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of dopamine D3, 5-HT2A and 5-HT2C receptor variants as pharmacogenetic determinants in tardive dyskinesia in African-Caribbean patients under chronic antipsychotic treatment: Curacao extrapyramidal syndromes study IX.
    Wilffert B; Al Hadithy AF; Sing VJ; Matroos G; Hoek HW; van Os J; Bruggeman R; Brouwers JR; van Harten PN
    J Psychopharmacol; 2009 Aug; 23(6):652-9. PubMed ID: 18562401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia.
    Basile VS; Masellis M; Badri F; Paterson AD; Meltzer HY; Lieberman JA; Potkin SG; Macciardi F; Kennedy JL
    Neuropsychopharmacology; 1999 Jul; 21(1):17-27. PubMed ID: 10379516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic association between the dopamine D3 receptor gene polymorphism (Ser9Gly) and tardive dyskinesia in patients with schizophrenia: a reevaluation in East Asian populations.
    Utsunomiya K; Shinkai T; Sakata S; Yamada K; Chen HI; De Luca V; Hwang R; Ohmori O; Nakamura J
    Neurosci Lett; 2012 Jan; 507(1):52-6. PubMed ID: 22172931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interactive effect of cytochrome P450 17alpha-hydroxylase and dopamine D3 receptor gene polymorphisms on abnormal involuntary movements in chronic schizophrenia.
    Segman RH; Heresco-Levy U; Yakir A; Goltser T; Strous R; Greenberg DA; Lerer B
    Biol Psychiatry; 2002 Feb; 51(3):261-3. PubMed ID: 11839369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of dopaminergic and serotonergic genes with tardive dyskinesia in patients with chronic schizophrenia.
    Segman RH; Goltser T; Heresco-Levy U; Finkel B; Shalem R; Schlafman M; Yakir A; Greenberg D; Strous R; Lerner A; Shelevoy A; Lerer B
    Pharmacogenomics J; 2003; 3(5):277-83. PubMed ID: 14583797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cebus apella, a nonhuman primate highly susceptible to neuroleptic side effects, carries the GLY9 dopamine receptor D3 associated with tardive dyskinesia in humans.
    Werge T; Elbaek Z; Andersen MB; Lundbaek JA; Rasmussen HB
    Pharmacogenomics J; 2003; 3(2):97-100. PubMed ID: 12746734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.